Background: The role of chemotherapy in metastatic non castrate prostate cancer (mNCPC) is debated. Survival benefits of docetaxel (D) added to androgen-deprivation therapy (ADT) were shown in the CHAARTED trial in patients with metastatic highvolume disease (HVD). Objective: To assess the impact of metastatic burden and to update overall...
-
August 2016 (v1)Journal articleUploaded on: December 4, 2022
-
August 2015 (v1)Journal article
Background: The Glass model developed in 2003 uses prognostic factors for noncastrate metastatic prostate cancer (NCMPC) to define subgroups with good, intermediate, and poor prognosis.Objective: To validate NCMPC risk groups in a more recently diagnosed population and to develop a more sensitive prognostic model.Design, setting, and...
Uploaded on: December 4, 2022